Skip to content

Genitourinary syndrome of menopause and its relief with estriol over 3 months

A cohort study on Genitourinary syndrome of menopause and its relief with estriol over 3 months

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/03/023903
Enrollment
100
Registered
2020-03-12
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N998- Other intraoperative and postprocedural complications and disorders of genitourinary system

Interventions

Intervention1: NA: NA

Sponsors

AIIMS Research Institute
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Sexual active women with sexual activity in the past 4 weeks 2. Women having a recent pap smear in the last 1 year

Exclusion criteria

Exclusion criteria: 1. Women on OAB drugs/ or who have undergone some Sui surgery 2. Women with POF 3. Women with surgical menopause 4. Women with an abnormal pap/abnormal endometrial thickness inappropriate for age. 5. Women with vaginal infections/ contact allergy/irritation 6. Women with vulvovaginal/urethral premalignant/ malignant lesions 7. Women with postmenopausal bleeding 8. Women with bilateral oophorectomy/ surgical menopause 9. Women with UTI(Urinary tract infections) 10. Women with history of estrogen dependent tumours 11. Pregnancy/Lactation 12. Women with SLE, Migraine, severe headaches 13. Women with unexplained vaginal bleeding 14. Increased risk of getting an estrogen sensitive cancer such as having a mother, sister or grandmother having a known, past or suspected breast cancer. 15. Women with unexplained vaginal bleeding 16. Women with history of heart attack, stroke, angina, liver disease, porphyria, hypertension, gall stones, diabetes mellitus, epilepsy, asthma or otosclerosis 17. Women with history of any bleeding disorder 18. Women who have received radiotherapy

Design outcomes

Primary

MeasureTime frame
use of local vaginal estrogen therapy is assosciated with significant improvement in womenâ??s self-reported prior bothersomeness and improvement in quality of life post treatmentTimepoint: after 3 months

Secondary

MeasureTime frame
NATimepoint: NA

Countries

India

Contacts

Public ContactDr Rajesh Kumari

All India Institute of Medical Sciences

drrajeshkumari@yahoo.com9911226176

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026